Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00021099 | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00036751 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00081276 | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00016289 | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00031993 | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00006486 | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00486538 | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | completed | Phase 2 | 53 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 4, 2013 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type(PaLiDo) | completed | Phase 2 | 33 | Vejle HospitalOTHER | 4 | Oct 26, 2012 | clinicaltrials |
| NCT00563836 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | completed | Phase 2 | 41 | Neovii BiotechINDUSTRY | 2 | Oct 3, 2012 | clinicaltrials |
| NCT00338884 | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | completed | Phase 2 | 120 | PfizerINDUSTRY | 6 | Aug 31, 2012 | clinicaltrials |
| NCT00030992 | BMS 247550 to Treat Kidney Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT01158534 | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00282048 | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer | completed | Phase 2 | 62 | PfizerINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00334295 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | completed | Phase 2 | 35 | AstraZenecaINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease(IMA901-202) | completed | Phase 2 | 68 | Immatics Biotechnologies GmbHINDUSTRY | 10 | Jul 10, 2012 | clinicaltrials |
| NCT00281515 | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Jun 29, 2012 | clinicaltrials |
| NCT00407563 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | completed | Phase 2 | 48 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 5, 2012 | clinicaltrials |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | completed | Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 2 | Mar 22, 2012 | clinicaltrials |
| NCT00197860 | Dendritic Cell Based Therapy of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00036036 | Study of CP-461 in Patients With Advanced Renal Cell Cancer | completed | Phase 2 | 14 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00267748 | Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) | completed | Phase 2 | 317 | PfizerINDUSTRY | 1 | Sep 5, 2011 | clinicaltrials |
| NCT00113529 | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00444314 | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 82 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | completed | Phase 1 / Phase 2 | 30 | Swedish Medical CenterOTHER | 1 | Feb 18, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT00077974 | A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | completed | Phase 2 | 106 | PfizerINDUSTRY | 1 | Oct 13, 2010 | clinicaltrials |
| NCT01176552 | Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer | completed | Phase 2 | 35 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT01182142 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | completed | Phase 2 | 51 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00848640 | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma(MERITS) | completed | Phase 2 | 75 | Egyptian Foundation For Cancer ResearchOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00254540 | Study of SU011248 in Patients With Advanced Kidney Cancer | completed | Phase 2 | 51 | PfizerINDUSTRY | 1 | Feb 23, 2010 | clinicaltrials |
| NCT00089648 | SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 61 | PfizerINDUSTRY | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2013source: clinicaltrials